Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis.

Airway inflammation in children younger than 5 yr of age is difficult to assess, particularly in patients with cystic fibrosis (CF). Furthermore, determining responses to therapies is often subjective in infants, especially those with CF. To determine whether airway DNA levels could be used as an index of airway inflammation, we measured DNA levels in bronchoalveolar lavage fluid (BALF), using a Hoechst dye-binding assay. BALF DNA levels and neutrophils from 16 infants with CF were compared with levels obtained from seven older CF patients and nine control children who underwent bronchoalveolar lavage for evaluation of other pulmonary diseases. BALF DNA was increased in both infants (3.2 +/- 0.7 microg/ml) and older patients with CF (5.4 +/- 0.9 microg/ml) compared with the controls (0.7 +/- 0.2 microg/ml) (mean +/- SEM). BALF DNA levels were not significantly different between infants and older patients with CF. BALF neutrophil counts in CF patients were significantly higher than in controls. Furthermore, BALF DNA levels and total neutrophil counts in infants with CF correlated positively with one another. We conclude that: (1) DNA levels were easily quantifiable in BALF of young children; (2) DNA levels in BALF from CF patients were greater than in a group of children with other pulmonary diseases, and that in some infants with CF, BALF DNA levels were equivalent to those of much older patients with CF; (3) DNA levels in BALF correlate with BALF neutrophil number, an index of inflammation; and (4) some infants with CF have increased levels of DNA in BALF, which may justify a clinical trial of aerosolized rhDNase in this population.

[1]  S. Douglas,et al.  Increased levels of interleukin-1 in bronchoalveolar washings from children with bacterial pulmonary infections. , 1990, The American review of respiratory disease.

[2]  S. Fitzsimmons,et al.  The changing epidemiology of cystic fibrosis. , 1993, The Journal of pediatrics.

[3]  A. Cantin,et al.  Cystic fibrosis lung inflammation: early, sustained, and severe. , 1995, American journal of respiratory and critical care medicine.

[4]  D. Riches,et al.  Early pulmonary inflammation in infants with cystic fibrosis. , 1995, American journal of respiratory and critical care medicine.

[5]  S. Shak,et al.  Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[6]  H. Boushey,et al.  Markers of mucus secretion and DNA levels in induced sputum from asthmatic and from healthy subjects. , 1993, The American review of respiratory disease.

[7]  R. Fick.  Pathogenesis of the pseudomonas lung lesion in cystic fibrosis. , 1989, Chest.

[8]  K. Paigen,et al.  A simple, rapid, and sensitive DNA assay procedure. , 1980, Analytical biochemistry.

[9]  M. Lethem,et al.  The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. , 1990, The European respiratory journal.

[10]  F. Accurso,et al.  Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. , 1991, The New England journal of medicine.

[11]  S. Soong,et al.  The chest roentgenogram in cystic fibrosis: a new scoring system. , 1979, Pediatrics.